gamma-aminobutyric acid has been researched along with Nociceptive Pain in 12 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Nociceptive Pain: Dull or sharp aching pain caused by stimulated NOCICEPTORS due to tissue injury, inflammation or diseases. It can be divided into somatic or tissue pain and VISCERAL PAIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study investigated whether the spinal or systemic treatment with the lipid resolution mediators resolvin D1 (RvD1), aspirin-triggered resolvin D1 (AT-RvD1) and resolvin D2 (RvD2) might interfere with behavioral and neurochemical changes in the mouse fibromyalgia-like model induced by reserpine." | 3.80 | Effects of D-series resolvins on behavioral and neurochemical changes in a fibromyalgia-like model in mice. ( Campos, MM; Klein, CP; Leite, CE; Maciel, IS; Souza, AH; Sperotto, ND, 2014) |
| "Multiple causes of neuropathic pain have been described and its incidence is likely to increase owing to the ageing global population, increased incidence of diabetes mellitus and improved survival from cancer after chemotherapy." | 2.55 | Neuropathic pain. ( Attal, N; Baron, R; Bennett, DL; Bouhassira, D; Colloca, L; Dickenson, AH; Dworkin, RH; Eccleston, C; Finnerup, NB; Freeman, R; Kalso, E; Ludman, T; Raja, SN; Truini, A; Yarnitsky, D, 2017) |
| "Neuropathic pain is caused by a lesion or disease of the somatosensory system, including peripheral fibres (Aβ, Aδ and C fibres) and central neurons, and affects 7-10% of the general population." | 2.55 | Neuropathic pain. ( Attal, N; Baron, R; Bennett, DL; Bouhassira, D; Colloca, L; Dickenson, AH; Dworkin, RH; Eccleston, C; Finnerup, NB; Freeman, R; Kalso, E; Ludman, T; Raja, SN; Truini, A; Yarnitsky, D, 2017) |
| "Corticosterone (CORT) is a glucocorticoid produced by adrenal glands under the control of the hypothalamic-pituitary-adrenal axis." | 1.42 | Corticosterone analgesia is mediated by the spinal production of neuroactive metabolites that enhance GABAergic inhibitory transmission on dorsal horn rat neurons. ( Anton, F; Darbon, P; Hanesch, U; Juif, PÉ; Poisbeau, P; Zell, V, 2015) |
| " Time-course data for the dose-response effects were analyzed using two-way analysis of variance and the posthoc Tukey-Kramer multiple-comparison test." | 1.40 | Antinociceptive effects of mirtazapine, pregabalin, and gabapentin after chronic constriction injury of the infraorbital nerve in rats. ( Hashimoto, R; Hosokawa, K; Mashimo, T; Nakae, A; Nakai, K, 2014) |
| "Neuropathic pain is currently an insufficiently treated clinical condition." | 1.40 | Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy. ( Hammock, BD; Inceoglu, B; Wagner, K; Yang, J, 2014) |
| " Noteworthy, the repeated administration of AT-RvD1 and RvD2 also prevented the depressive-like behavior in reserpine-treated animals, according to assessment of immobility time, although the chronic administration of pregabalin failed to affect this parameter." | 1.40 | Effects of D-series resolvins on behavioral and neurochemical changes in a fibromyalgia-like model in mice. ( Campos, MM; Klein, CP; Leite, CE; Maciel, IS; Souza, AH; Sperotto, ND, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (91.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ryu, SW | 1 |
| Kim, YO | 1 |
| Kim, HB | 1 |
| Oh, SB | 2 |
| Choi, JI | 1 |
| Yoon, MH | 1 |
| Lee, PR | 1 |
| Yoon, SY | 1 |
| Kim, HW | 1 |
| Yeo, JH | 1 |
| Kim, YH | 1 |
| García-Hernández, L | 1 |
| Navarrete-Vázquez, G | 1 |
| González-Trujano, ME | 1 |
| López-Muñoz, FJ | 1 |
| Déciga-Campos, M | 1 |
| Enomoto, R | 1 |
| Tsukamoto, M | 1 |
| Shimoshige, Y | 1 |
| Aoki, T | 1 |
| Matsuoka, N | 1 |
| Nakai, K | 1 |
| Nakae, A | 1 |
| Hashimoto, R | 1 |
| Mashimo, T | 1 |
| Hosokawa, K | 1 |
| Wagner, K | 1 |
| Yang, J | 1 |
| Inceoglu, B | 1 |
| Hammock, BD | 1 |
| Klein, CP | 1 |
| Sperotto, ND | 1 |
| Maciel, IS | 1 |
| Leite, CE | 1 |
| Souza, AH | 1 |
| Campos, MM | 1 |
| Nakama-Kitamura, M | 1 |
| Zell, V | 1 |
| Juif, PÉ | 1 |
| Hanesch, U | 1 |
| Poisbeau, P | 1 |
| Anton, F | 1 |
| Darbon, P | 1 |
| Adães, S | 1 |
| Ferreira-Gomes, J | 1 |
| Mendonça, M | 1 |
| Almeida, L | 1 |
| Castro-Lopes, JM | 1 |
| Neto, FL | 1 |
| Colloca, L | 1 |
| Ludman, T | 1 |
| Bouhassira, D | 1 |
| Baron, R | 1 |
| Dickenson, AH | 1 |
| Yarnitsky, D | 1 |
| Freeman, R | 1 |
| Truini, A | 1 |
| Attal, N | 1 |
| Finnerup, NB | 1 |
| Eccleston, C | 1 |
| Kalso, E | 1 |
| Bennett, DL | 1 |
| Dworkin, RH | 1 |
| Raja, SN | 1 |
| Vedula, SS | 1 |
| Goldman, PS | 1 |
| Rona, IJ | 1 |
| Greene, TM | 1 |
| Dickersin, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| BotulInum Toxin Type A for Peripheral Neuropathic Pain in subjEcts With Carpal Tunnel Syndrome: a Multicenter, Randomized, Doubleblind, Placebo-controlled Study[NCT05411900] | Phase 2 | 164 participants (Anticipated) | Interventional | 2022-05-25 | Recruiting | ||
| Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management: A Randomized Controlled Trial of Efficacy and Safety[NCT05427058] | 36 participants (Anticipated) | Interventional | 2022-08-01 | Not yet recruiting | |||
| Neuropathic Foot and Ankle in Rheumatoid Arthritis : Ultrasound and Nerve Conduction Study[NCT04550884] | 80 participants (Anticipated) | Observational | 2020-10-31 | Not yet recruiting | |||
| NanaBis™ an Oro-buccal Administered Equimolar d9-THC & CBD Formulation as Monotherapy for Management of Opioid Requiring Bone Pain Due to Metastatic Cancer: Phase 3 Multi Centre Blinded Randomized Withdrawal Active & Placebo Controlled Trial[NCT04808531] | Phase 3 | 360 participants (Anticipated) | Interventional | 2023-11-30 | Not yet recruiting | ||
| Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.[NCT06030297] | 301 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for gamma-aminobutyric acid and Nociceptive Pain
| Article | Year |
|---|---|
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
11 other studies available for gamma-aminobutyric acid and Nociceptive Pain
| Article | Year |
|---|---|
Antinociceptive effect of intrathecal P7C3 via GABA in a rat model of inflammatory pain.
Topics: Analgesics; Animals; Calcium Signaling; Carbazoles; Disease Models, Animal; Formaldehyde; gamma-Amin | 2021 |
Peripheral GABA
Topics: Animals; Antibodies; Freund's Adjuvant; GABA-A Receptor Agonists; GABA-A Receptor Antagonists; gamma | 2018 |
Antihyperalgesic activity of a novel synthesized analogue of lidocaine in diabetic rats.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Diabetes Complications; | 2013 |
New index of pain triggered by spinal activation of voltage-dependent sodium channels.
Topics: Amitriptyline; Animals; gamma-Aminobutyric Acid; Injections, Spinal; Lidocaine; Male; Mexiletine; Mi | 2013 |
Antinociceptive effects of mirtazapine, pregabalin, and gabapentin after chronic constriction injury of the infraorbital nerve in rats.
Topics: Adrenergic alpha-Antagonists; Amines; Analgesics; Animals; Cranial Nerve Injuries; Cyclohexanecarbox | 2014 |
Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy.
Topics: Amines; Analgesics; Animals; Benzoates; Chronic Pain; Conditioning, Psychological; Cyclohexanecarbox | 2014 |
Effects of D-series resolvins on behavioral and neurochemical changes in a fibromyalgia-like model in mice.
Topics: Analgesics; Animals; Antidepressive Agents; Brain; Depression; Disease Models, Animal; Docosahexaeno | 2014 |
The distinctive significance of analgesic drugs and olfactory stimulants on learned pain in mice.
Topics: Acetaminophen; Amines; Analgesics; Animals; Conditioning, Psychological; Cyclohexanecarboxylic Acids | 2014 |
Corticosterone analgesia is mediated by the spinal production of neuroactive metabolites that enhance GABAergic inhibitory transmission on dorsal horn rat neurons.
Topics: Animals; Blood Chemical Analysis; Corticosterone; Desoxycorticosterone; gamma-Aminobutyric Acid; Mic | 2015 |
Injury of primary afferent neurons may contribute to osteoarthritis induced pain: an experimental study using the collagenase model in rats.
Topics: Amines; Analgesics; Animals; Arthritis, Experimental; Calcium Channels; Calcium Channels, L-Type; Co | 2015 |
Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin litigation.
Topics: Access to Information; Amines; Analgesics; Antimanic Agents; Authorship; Bipolar Disorder; Clinical | 2012 |